Sygnis Pharma completes patient enrollment in ischemic stroke drug trial
The study aims to investigate the efficacy and safety of AX200 as a treatment for acute ischemic stroke. The company anticipates to release initial findings of the AXIS
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.